Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Hemophilia treatment market is driven by aging populations increasing acquired cases, government-backed early diagnosis, and ...

To evaluate the usefulness of this concentrate in patients with hemophilia B, the dose response, the distribution and turnover of factor IX and the hemostatic effectiveness after intravenous ...

This year's Manila Pen Show felt extra special for columnist Alliah Czarielle and her family. It was a lesson on finding ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg ...

Hemophilia B is an X-linked recessive hemorrhagic disorder caused by a deficiency or abnormality of clotting factor IX. Human factor IX is a vitamin-K-dependent multidomain glycoprotein composed ...

A lack or decrease of clotting factor IX (FIX) causes hemophilia B, also called Christmas disease. Hemophilia B is four times less common than hemophilia A, according to the National Hemophilia ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

The hemophilia treatment landscape is rapidly evolving, with newly launched therapies and gene therapies joining factor replacement therapies, Hemlibra, and Altuvio to ...

"She joins Be Bio at an ideal time, with enrollment now underway in the BeCoMe-9 trial for BE-101 in Hemophilia B, and with our development candidate, BE-102, progressing toward IND as a potential ...